IDEAYA Biosciences, Inc. (IDYA): Total Liabilities
$86.39M
As of 2025-12-31
$110.79M
As of 2026-06-30
+30.9%
3-year compound annual growth
-2.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $86.39M | +33.0% | 2026-02-17, Balance as of period end |
| 2024-12-31 | $64.94M | +130.1% | 2026-02-17, Balance as of period end |
| 2023-12-31 | $28.23M | -26.7% | 2025-02-18, Balance as of period end |
| 2022-12-31 | $38.51M | -51.8% | 2024-02-20, Balance as of period end |
| 2021-12-31 | $79.83M | -20.2% | 2023-03-07, Balance as of period end |
| 2020-12-31 | $100.00M | +693.5% | 2022-03-18, Balance as of period end |
| 2019-12-31 | $12.60M | +77.5% | 2021-03-23, Balance as of period end |
| 2018-12-31 | $7.10M | n/a | 2020-03-24, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $86.39M | +33.0% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $161.76M | +37.5% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $211.49M | +6.2% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $85.96M | -29.1% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $343.95M | +27.5% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $34.89M | -21.3% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $210.17M | -7.7% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $362.11M | -9.9% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $397.87M | -7.7% |
Compare IDYA, VNDA, AMRN, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗